Wegovy vs Mounjaro Side Effects: A Head-to-Head Comparison for Women

What These Two Drugs Actually Are

Wegovy and Mounjaro work differently at the receptor level, and that difference shapes their side-effect profiles in ways that matter specifically to you as a woman.

Wegovy is semaglutide 2.4 mg, a GLP-1 receptor agonist approved by the FDA for chronic weight management in adults with a BMI of 30 or higher, or BMI <27 with at least one weight-related condition. It mimics the gut hormone glucagon-like peptide-1, slowing gastric emptying, reducing appetite signals in the hypothalamus, and stimulating insulin secretion in a glucose-dependent way.

Mounjaro is tirzepatide, a dual GIP/GLP-1 receptor agonist. Adding glucose-dependent insulinotropic polypeptide (GIP) activation on top of GLP-1 action is the key mechanistic difference. Tirzepatide's dual mechanism appears to produce greater weight loss at comparable tolerability, though no single randomized controlled trial has placed these two drugs directly against each other at their FDA-approved weight-loss doses.

Why the receptor difference matters for women

GLP-1 receptors are expressed in the ovaries, uterus, and placenta. GIP receptors are also present in adipose tissue, where women carry a higher proportion of subcutaneous fat than men. Whether this changes clinical outcomes in women specifically has not been formally studied, which is an honest gap in the current evidence.

The trial field you need to understand

The STEP-1 trial (NEJM 2021) enrolled 1,961 adults without diabetes and showed a mean body-weight reduction of 14.9% with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo. The SURPASS-2 trial (NEJM 2021) compared tirzepatide to semaglutide 1 mg (not 2.4 mg) in people with type 2 diabetes, showing greater A1C reduction and weight loss with tirzepatide across all three doses tested 5 mg, 10 mg, 15 mg. SURMOUNT-1 (NEJM 2022) showed tirzepatide 15 mg produced a mean weight loss of 20.9% at 72 weeks in adults without diabetes.

No published head-to-head randomized trial has compared semaglutide 2.4 mg directly against tirzepatide at its full weight-loss dose range. The side-effect comparison below synthesizes data across these separate trials.

GI Side Effects: The Ones Every Woman Asks About

Gastrointestinal symptoms are the dominant side-effect category for both drugs. They are not identical in frequency or character, and the differences are clinically meaningful.

Nausea

In STEP-1, nausea occurred in approximately 44% of semaglutide participants versus 16% with placebo. In SURMOUNT-1, nausea was reported in 31 to 33% of participants on tirzepatide 15 mg. Both figures come from populations that included a higher proportion of women than men, reflecting real-world weight-management demographics.

Nausea with both drugs peaks during dose escalation and typically resolves within the first four to eight weeks at any given dose level. If you are still nauseated at week ten on a stable dose, that is worth raising with your prescriber rather than waiting it out.

Vomiting and diarrhea

In STEP-1, vomiting affected about 24% and diarrhea about 30% of semaglutide users. Tirzepatide's SURMOUNT-1 data showed vomiting in approximately 10% and diarrhea in 22% at the 15 mg dose. These are cross-trial comparisons from separate study populations, so direct numerical comparison has limits.

Constipation

Constipation runs counter to the diarrhea narrative many women expect. In STEP-1, constipation occurred in 24% of semaglutide participants. Tirzepatide's constipation rate in SURMOUNT-1 was approximately 17% at 15 mg. Slowed gastric motility is the mechanism for both.

For women who already deal with constipation related to irritable bowel syndrome (which disproportionately affects women), hypothyroidism, or progesterone dominance in the luteal phase, this side effect deserves explicit anticipatory counseling before you start either drug.

Gastroparesis and gastric-emptying delay

Both drugs slow gastric emptying measurably. FDA labeling for semaglutide notes that it may affect oral drug absorption, including oral contraceptives. This is not theoretical. If you take a combined oral contraceptive pill, ask your clinician whether a non-oral method (patch, ring, IUD, injection) is preferable while on either of these drugs, particularly during the first three months.

Side Effects That Show Up Differently in Women

The framework below is one you will not find assembled this way elsewhere. It organizes the sex-specific side-effect considerations across reproductive life stages for GLP-1 and dual GIP/GLP-1 agonists.

Menstrual cycle changes

Neither drug's prescribing information lists menstrual irregularity as a labeled adverse event, but this is an area where the clinical picture is incomplete. Rapid weight loss of any cause can disrupt the hypothalamic-pituitary-ovarian axis and suppress ovulation. A weight loss of 5 to 10% body weight has been shown to restore ovulatory cycles in some women with PCOS, while loss beyond 15% in women with a lower baseline BMI can suppress menstruation through hypothalamic amenorrhea.

Women in the STEP trials were not systematically asked about cycle changes. That is the honest evidence gap: we lack prospective menstrual-cycle data from STEP-1 or SURMOUNT-1.

PCOS and androgen excess

Both drugs reduce insulin resistance, which is central to the androgen excess of PCOS. A 2023 systematic review in Fertility and Sterility found that GLP-1 receptor agonists improved menstrual regularity, lowered free testosterone, and reduced BMI in women with PCOS, though most studies used liraglutide or low-dose semaglutide rather than 2.4 mg or tirzepatide specifically.

Tirzepatide's additional GIP action may offer a modest advantage in women with PCOS who have prominent insulin resistance, because GIP signaling influences adipose tissue insulin sensitivity directly. This hypothesis has not been tested in a PCOS-specific tirzepatide trial.

Perimenopause

Perimenopausal women face a specific challenge. Falling estrogen levels slow gastric motility independently of GLP-1 drugs. Combining that baseline change with either semaglutide or tirzepatide can intensify constipation and bloating beyond what younger women typically report. Dose escalation may need to proceed more slowly in this group.

Estrogen also modulates GLP-1 receptor expression. Animal models suggest that estrogen upregulates GLP-1 receptor sensitivity in the gut, which may mean perimenopausal and postmenopausal women experience more pronounced GI effects per unit dose. Human PK data in this subgroup are limited, and this is an area where extrapolation from general adult trials is the current standard of practice.

Bone and muscle

Both drugs produce weight loss that includes lean mass loss, not just fat. This is more concerning for women because peak bone mass is lower in women than men, and postmenopausal bone loss accelerates independently of body weight. In STEP-1, lean body mass loss represented approximately 40% of total weight lost. Resistance training and adequate protein intake (at minimum 1.2 g per kg body weight) are not optional adjuncts for women on these drugs. They are essential.

Hair loss (telogen effluvium)

Telogen effluvium, a temporary shedding of hair triggered by physiologic stress including rapid weight loss, has been reported with both drugs and emerged as a notable patient concern in FDA adverse-event reporting data. It is not specific to either drug and is driven primarily by caloric deficit and rapid weight change. Women with a personal or family history of female-pattern hair loss may want to discuss this risk before starting. Hair typically regrows over three to six months once weight loss stabilizes.

Serious but Rare Side Effects: What the Data Actually Say

Both drugs carry an FDA black-box warning for thyroid C-cell tumors based on rodent studies. The FDA label for Wegovy states that relevance to humans has not been established, and both drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.

Pancreatitis

Acute pancreatitis has been reported with both semaglutide and tirzepatide. Across the STEP trials, pancreatitis was confirmed in 0.3% of semaglutide participants. Tirzepatide trials reported similar low rates. Women with hypertriglyceridemia (which can be worse in perimenopausal years when estrogen drops) carry higher baseline pancreatitis risk and should be screened before starting either drug.

Gallbladder disease

Rapid weight loss of any kind increases biliary sludge and gallstone formation. In STEP-1, cholelithiasis or cholecystitis was reported in 2.6% of semaglutide participants versus 1.2% in the placebo group. Tirzepatide trials showed comparable gallbladder event rates. Women already have twice the gallstone risk of men at baseline, so this is an important counseling point.

Cardiovascular effects

The SELECT trial (NEJM 2023) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and overweight or obesity but without diabetes. Tirzepatide's cardiovascular outcomes trial (SURMOUNT-MMO) is ongoing. Women were underrepresented in SELECT (about 28% of participants), which limits direct application of the CV benefit data to women.

Pregnancy, Lactation, and Contraception: Read This Before You Start

Both Wegovy and Mounjaro are contraindicated in pregnancy. This is not a precautionary gray area. Animal studies have shown embryo-fetal toxicity with both drugs at clinically relevant exposures, including fetal growth restriction and skeletal abnormalities with semaglutide. Human pregnancy data are limited but do not currently establish safety.

ACOG recommends discontinuing GLP-1 receptor agonists before conception. The standard clinical recommendation is to stop Wegovy at least two months before a planned conception attempt, given semaglutide's half-life of approximately one week and the time needed to clear systemic exposure. For Mounjaro, tirzepatide has a similar half-life of approximately five days; the same two-month washout window is recommended by most prescribers, though no formal guideline has set a different interval.

Oral contraceptive interactions

As noted above, both drugs slow gastric emptying. This may reduce the absorption of oral contraceptives. The Wegovy prescribing information advises using a non-oral contraceptive method or adding a barrier method for four weeks after starting semaglutide and for four weeks after each dose increase. Women using combined oral contraceptives should review this interaction with their prescriber.

Lactation

Neither drug has adequate human lactation data. Animal studies show tirzepatide is present in milk. The FDA label for both drugs states that the benefits of breastfeeding should be weighed against potential risk to the infant. Most clinicians advise against using either drug while breastfeeding given the lack of safety data and the availability of other weight-management options.

Fertility and the PCOS paradox

Here is the clinical nuance that matters most: because both drugs can restore ovulatory cycles in women with PCOS who were previously anovulatory, unintended pregnancy is a real risk for women who assume they cannot conceive. Effective contraception is essential for any woman on either drug who does not want to become pregnant, including those who have been told their fertility is reduced.

Who This Is Right For (and Who Should Think Twice)

Women likely to benefit from Mounjaro over Wegovy

• You have type 2 diabetes or prediabetes with significant insulin resistance, because SURPASS-2 showed tirzepatide 15 mg reduced A1C by 2.3 percentage points versus 1.86 percentage points with semaglutide 1 mg.
• You want the highest available weight-loss ceiling, given SURMOUNT-1 data showing mean loss above 20%.
• You experienced significant nausea on a GLP-1-only agent previously; the dual mechanism may be better tolerated by some women, though this is not guaranteed.

Women likely to benefit from Wegovy over Mounjaro

• You have established cardiovascular disease. SELECT trial data supports a 20% MACE reduction specifically with semaglutide 2.4 mg, data that do not yet exist for tirzepatide.
• Cost and insurance access are factors. Wegovy has broader formulary coverage in some plans as of mid-2025.
• You are in the perimenopausal or postmenopausal years and already managing GI motility issues; some clinicians prefer starting with the agent whose GI profile is better characterized in older adult subgroups.

Women who should discuss carefully with their clinician before starting either

• History of pancreatitis or high triglycerides.
• Personal or family history of medullary thyroid carcinoma or MEN2.
• Active eating disorder history, where appetite suppression requires careful psychiatric co-management.
• Planning pregnancy within the next six months.
• Breastfeeding.
• Hypothyroidism that is not yet stably treated, because weight change affects levothyroxine dosing.

Tolerability Management: Practical Steps That Work

Neither drug requires you to simply endure nausea. Both have escalation schedules designed to limit peak GI exposure, and deviating from those schedules on your own is one of the most common causes of unnecessary discontinuation.

For Wegovy, the standard escalation starts at 0.25 mg weekly for four weeks, increasing every four weeks to a target of 2.4 mg. For Mounjaro, the start is 2.5 mg weekly for four weeks, titrating up in 2.5 mg increments every four weeks toward 15 mg. If GI side effects are unacceptable at any step, your prescriber can hold you at the current dose for an extra four weeks rather than escalating. This is supported by the trial protocols used in STEP-1 and SURMOUNT-1.

Practical steps that reduce GI side effects for both drugs:

• Eat smaller, lower-fat, lower-fiber meals in the 48 hours after your injection.
• Take your injection at night so peak drug absorption overlaps with sleep.
• Stay well hydrated, particularly if diarrhea is prominent.
• Ginger tea and small-volume protein-forward meals help some women; there is no randomized trial evidence for specific dietary interventions, but patient reports are consistent.
• Discuss ondansetron or prochlorperazine with your prescriber if nausea is severe enough to affect daily function.

A Note on the Evidence Gap for Women Specifically

Women were the majority of participants in STEP-1 (roughly 74%) and SURMOUNT-1 (roughly 67%). That is better representation than most cardiovascular trials. Still, neither trial published pre-specified sex-stratified efficacy or safety analyses as primary endpoints. Secondary analyses from STEP trials suggest women and men experience comparable weight loss percentages, but the data on sex-specific side-effect rates are not published with the granularity that would let us say with confidence that nausea or constipation rates are meaningfully different between women and men in these trials.

This transparency matters because it affects how firmly you should take any claim that "women respond better to X than Y." The current evidence does not support that level of specificity. What we can say is that the GI side-effect burden for both drugs is real, manageable, and front-loaded in the first three to six months.

Switching From Wegovy to Mounjaro (or the Reverse)

Switching is feasible and done in practice, though no published trial has examined optimal switching protocols between these two drugs specifically.

The most common clinical approach: start tirzepatide at 2.5 mg the week after your last semaglutide dose, given that both drugs have half-lives under ten days and back-to-back administration without a washout period is generally considered safe by most obesity medicine specialists. The Obesity Medicine Association has published general guidance on GLP-1 transitions, but specific semaglutide-to-tirzepatide protocols remain at prescriber discretion.

Expect a possible GI flare on restart, even if you tolerated your previous drug well. Starting at the lowest tirzepatide dose and re-escalating from there is standard practice regardless of how long you were on semaglutide or how high your previous dose was.